Ask AI
ProCE Banner Activity

Integrating Bispecific Antibodies in Follicular Lymphoma: Practical Insights on Sequencing, Safety, and Patient Selection

Clinical Thought

This expert commentary provides practical guidance on incorporating CD20-targeted bispecific antibodies into the evolving treatment landscape of follicular lymphoma, addressing sequencing considerations, epitope differences, baseline risk assessment, toxicity management, and real-world patient selection strategies to support safe and effective integration into clinical practice.

Released: March 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Genentech, a member of the Roche Group and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Regeneron Pharmaceuticals, Inc

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, advanced practice providers, and other healthcare professionals caring for patients with follicular lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the mechanism of action of novel and investigational bispecific antibodies for treating follicular lymphoma

  • Integrate clinical trial data, guideline recommendations, and patient-specific factors to aid in refining individualized treatment plans, including therapy sequencing, for the use of bispecific antibodies in patients with follicular lymphoma

  • Manage TRAEs associated with bispecific antibodies, using best practices and patient counseling, to emphasize the importance of reporting and addressing toxicities to improve adherence to therapy, patient quality of life, and clinical outcomes

Disclosure

Primary Author

Loretta J. Nastoupil, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Genmab, Regeneron; researcher: Bristol Myers Squibb, Genentech, Gilead/Kite, Novartis, Takeda.